BioNexus Gene Lab Corp (BGLC)
↓ Download CSV- Sector Services
- Incorporated WY
- Fiscal year ends Dec 31
In fiscal 2025, BioNexus Gene Lab Corp reported revenue of $7.42M, down 21.9% from the prior year. The company ran a net loss, with a net margin of -40.2% and a gross margin of 14.6%. It held $9.25M in total assets against $637.9K in total liabilities.
Key ratios (FY2025)
14.6%
Gross margin
-39.9%
Operating margin
-40.2%
Net margin
-34.6%
Return on equity
-21.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.42M | $9.51M | $9.77M | $10.93M | $13.36M | $11.39M | $127.0K | $212.3K |
| Cost of Revenue | $6.34M | $8.22M | $8.44M | $9.67M | $11.10M | $9.67M | $71.1K | -$183.6K |
| Gross Profit | $1.09M | $1.29M | $1.33M | $1.26M | $2.27M | $1.72M | $55.9K | $28.8K |
| Operating Income | -$2.97M | -$1.57M | -$2.59M | -$291.2K | $1.06M | $1.27M | -$275.7K | $59.9K |
| Net Income | -$2.98M | -$1.60M | -$2.63M | -$356.0K | $751.6K | $1.09M | -$246.5K | $26.5K |
| EPS (Diluted) | — | $-0.09 | $-0.17 | — | — | — | — | — |
| Total Assets | $9.25M | $10.43M | $11.40M | $8.74M | $9.57M | $10.12M | $1.23M | $1.65M |
| Total Liabilities | $637.9K | $2.11M | $1.74M | $2.08M | $2.39M | $3.45M | $108.9K | $130.3K |
| Shareholders' Equity | $8.61M | $8.32M | $9.66M | $6.67M | $7.18M | $6.66M | $1.12M | $1.52M |
| Cash & Equivalents | $2.49M | $2.89M | — | — | $2.12M | $2.79M | $859.1K | $1.26M |
| Operating Cash Flow | -$1.84M | -$2.09M | -$1.82M | $551.8K | $9.2K | $552.7K | -$217.3K | -$274.1K |
| Capital Expenditures | $37.0K | $227.0K | $149.4K | $0 | $3.2K | $421.6K | $12.8K | -$39.6K |
| Shares Outstanding | 2.42M | 1.80M | 17.67M | 14.48M | 171.22M | 171.22M | 102.73M | 74.63M |